They haven't initiated the expansion trial yet. They will review the phase 1a data at the end of this year before deciding to go ahead with the expansion cohort.
And the presentation at ASCO is outlining the trial design and objectives of the phase 1b. It was likely selected because it is such a promising novel treatment with quite an interesting route of administration. And the logistics of a CAR T trial, including manufacturing and transport, presents unique challenges.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
